WHO 药品预认证与检查动态·· 13 天前AI 评分59
WHO 将 Ipca 三种规格磷酸伯氨喹片剂列入预认证清单
Ipca’s Primaquine pediatric products prequalified
AI 导读
WHO 药品预认证团队于 2026 年 9 月 23 日将 Ipca（印度）的三种磷酸伯氨喹片剂列入预认证清单，编号 MA206、MA207、MA208 分别对应 2.5 mg、5 mg 和 7.5 mg。公告称这些产品用于预防间日疟原虫和卵形疟原虫疟疾的复发。
正文
News
23 September, 2026 - 00:12 (CEST)
Announcement
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
- MA206 Primaquine (as phosphate) Tablets 2.5 mg – Ipca, India
- MA207 Primaquine (as phosphate) Tablets 5 mg – Ipca, India
- MA208 Primaquine (as phosphate) Tablets 7.5 mg – Ipca, India
These products are used in the prevention of relapse of Plasmodium vivax and Plasmodium ovale malaria
来源：WHO 药品预认证与检查动态 · extranet.who.int